Celebrex Web News Log

elecoxib (CELEBREX) May Double the Risk for Heart Attacks

Mon, 1 May 2006 06:57:34 -0400

DO NOT USE! Celecoxib (CELEBREX) May Double the Risk for Heart Attacks Compared to Older Arthritis Drugs May 2006. New research published in the March 2006 edition of the Journal of the Royal Society of Medicine indicates that the popular arthritis and painkilling drug celecoxib (CELEBREX) may double the risk for heart attacks compared to older arthritis medications. You should not use celecoxib. The best evidence at this time indicates that the older drugs such as naproxen, ibuprofen, and acetaminophen are safer for the heart.

Can Celebrex Lower Odds for Oral Cancer but Boost Heart Disease Risk? Study does not show cancer prevention for Bextra.

Fri, 7 Oct 2005 10:00:36 -0400

Long-term use of non-steroidal anti-inflammatory drugs ( NSAIDs) shows promise in preventing mouth cancer in former and current smokers but may pose a heart risk, according to a Norwegian study in this week's issue of The Lancet. The study did not include data on use of the cox-2 inhibitor subclass of NSAIDs, which includes Vioxx, Celebrex and Bextra

http://news.yahoo.com/news?tmpl=story&u=/hsn/20051007/hl_hsn/nsaidsloweroddsfororalcancerbutboostheartdiseaserisk

See the results of our latest poll, in which we asked site users if prescription medicines should be advertised directly to the public, e.g. on television.

Thu, 12 May 2005 07:51:31 -0400

Irish Health News Poll

Serious injury or death can occur when patients with implanted neurological stimulators undergo MRI procedures

Tue, 10 May 2005 07:54:00 -0400

Date: Tue, 10 May 2005 15:01:23 -0400
From: CDER MEDWATCH LISTSERV
Subject: FDA MedWatch - MRI-Caused Injuries in Patients with Implanted Neu rological Stimulators

MedWatch - The FDA Safety Information and Adverse Event Reporting Program

FDA notified healthcare professionals that serious injury or death can occur when patients with implanted neurological stimulators undergo MRI procedures. The FDA received several reports of serious injury, including coma and permanent neurological impairment. The mechanism for these adverse events is likely to involve heating of the electrodes at the end of the leadwires, resulting in injury to the surrounding tissue. The public health notification also offered recommendations for preventive actions.

CELEBREX AND BEXTRA: A BETTER WAY TO MAKE THESE DRUGS SAFER

Mon, 9 May 2005 11:07:26 -0400

Celebrex: Lawyer: Monheit Law: Side Effects: Heart Attack: ________

Just Posted at www.medicationsense.com

On February 18, a blue-ribbon FDA Advisory Committee found that COX-2 anti-inflammatory drugs (Celebrex, Bextra) increase the risk of heart attacks and strokes and recommended stronger warnings for these drugs. However, even at their lowest available doses, Celebrex and Bextra are very strong drugs and risks may remain. Research has shown that even lower, safer doses are effective, but these 50% to 75% lower doses are not marketed by the manufacturer. Dr. Cohen's new article describes what you and your doctor should know and what you can do about using Celebrex or Bextra more safely.

Ask Monheit Law, "Do I have a Celebrex Case?"

For more information, contact:
Michael Monheit, Esquire, Monheit Law, PC

Dr. Sidney Wolfe, director of Public Citizen’s Health Research Group, talking about Public Citizen’s new book, Worst Pills, Best Pills

Tue, 29 Mar 2005 07:41:48 -0400

Tune in to ABC’s Good Morning America on Wednesday morning to see Dr. Sidney Wolfe, director of Public Citizen’s Health Research Group, talking about Public Citizen’s new book, Worst Pills, Best Pills, which provides comprehensive information about 538 prescription drugs and warns of 181 drugs that are unsafe or ineffective.

The book is particularly valuable because Dr. Wolfe has a strong track record of identifying dangerous drugs well before federal regulators take action to ban or put warnings on these drugs. For example, in April 2001, Dr. Wolfe warned consumers not to take Vioxx because it increases the risk of heart attack. But it wasn’t until last fall that Merck pulled the drug from shelves, citing its increased heart attack risk.

Vioxx was the ninth prescription drug to be taken off the market in the past seven years that Public Citizen had previously warned consumers not to use. For four of the drugs - Vioxx, Baycol, Rezulin and Serzone - Public Citizen issued warnings more than two years before their removal from the market. Similarly, Public Citizen warned patients not to use Celebrex three and a half years before the government announced that a study showed it increased heart risks.

On Good Morning America, Dr. Wolfe will discuss problems with the drug approval process, explain how dangerous prescription drugs get onto the market and tell viewers why neither the government nor drug manufacturers are responsive when alerted to serious adverse effects of a drug. He will tell viewers about a Web site that accompanies the book, (www.WorstPills.org), which contains the contents of the book in a user-friendly, searchable database format.

Good Morning America comes on at 7 a.m. on ABC.

Problems With COX-2 Inhibitors

Tue, 1 Mar 2005 07:50:15 -0400

Vault Meloxicam (MOBIC) To Blockbuster Status. There is no medical reason why you should be taking meloxicam rather than an older, equally effective NSAID such as ibuprofen to manage arthritis.

FDA action on Tysabri

Tue, 1 Mar 2005 07:45:16 -0400

FDA MedWatch: Tysabri (natalizumab) marketing suspended due to serious adverse events reported with use

Bush's Tort Reform Must Take Victims Into Account

Mon, 28 Feb 2005 07:44:31 -0400

Bush's push for tort reform has been focusing on "rich" trial lawyers that profit from filing class-action lawsuits. Bush has failed to see the numerous changes that have been made as a result of these lawsuits. The author believes the victims should be his first priority and not awards or insurance premiums. Detroit Free Press, Detroit Free Press 02/28/2005

Weigh options to risky painkillers

Sun, 27 Feb 2005 07:43:19 -0400

Gainesville Sun, Sun, 27 Feb 2005 3:06 AM PST Weigh options to risky painkillers, expert says University of Florida rheumatologist who specializes in treating a number of chronic pain conditions is urging physicians and their patients to carefully consider all the alternatives before using drugs in a family known as COX-2 inhibitors.